At the end of the latest market close, Halozyme Therapeutics, Inc. (HALO) was valued at $18.77. In that particular session, Stock kicked-off at the price of $20 while reaching the peak value of $20.06 and lowest value recorded on the day was $19.04. The stock current value is $19.88.
Halozyme Therapeutics, Inc. had a pretty favorable run when it comes to market performance. The 1-year high price for the company’s stock is recorded $19.73 on 01/14/20, with the lowest value was $14.61 for the same time period, on 11/04/19.
Halozyme Therapeutics, Inc. (HALO) full year performance was 27.27%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Halozyme Therapeutics, Inc. shares are logging 0.76% during the 52-week period from to high price, and 36.07% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $14.61 and $19.73.
The company’s shares, operating in the sector of healthcare managed to top a trading volume set approximately around 2.62 million for the day, which was evidently higher when compared to average daily volumes of the shares.
When it comes to year-to-date metrics, the company recorded performance in the market by 12.13%, having the revenues showcasing 26.62% on a quarterly basis in comparison for the same period the last year. At the time of this writing, the total market value of the company is set at 2.95B, with the company having 281 employees.
The Analysts eye on Halozyme Therapeutics, Inc.(HALO)
According to the data provided on Barchart.com, the moving average for the company in the 100-day period was set at 17.10, with a change in the price noted at +3.11. In a similar fashion, Halozyme Therapeutics, Inc. recorded a movement of +18.55% for the period of the last 100 days, recording 1,394,117 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt the company is using in order to support assets, correlating with the value of shareholders’ equity. The total Debt to Equity ratio for HALO is recording 0.26 concluded with the time of this writing. In addition, long term Debt to Equity ratio is set at 0.04.
Technical Lookout on Halozyme Therapeutics, Inc. (HALO)
Raw Stochastic average of Halozyme Therapeutics, Inc. in the period of last 50 days is set at 96.70%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 92.89%. In the last 20 days, the company’s Stochastic %K was 79.09% and its Stochastic %D was recorded at 77.33%.
Taking into consideration the past performance of Halozyme Therapeutics, Inc., multiple moving trends are noted. Price performance for year-to-date for the company’s stock appears to be pessimistic, given the fact the metric is recording 12.13%. Additionally, trading for the stock in the period of the last six months notably improved to 17.22%, alongside a boost of 27.27% for the period of the last 12 months. The shares increased approximately by 9.08% in the 7-day charts and went up by 11.56% in the period of the last 30 days. Common stock shares were driven by 26.62% for the lastly recorded quarter.